Company Overview
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -30.58% |
| 6 Months: | -20.00% |
| 3 Months: | +44.83% |
| 1 Month: | +22.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 35.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALZN Alzamend Neuro, Inc. PHARMA | 1.68 | -0.64 | $8.11M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2020 | Oct 2020 | Jan 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.32M | -1.30M | -1.12M | -2.31M | -3.58M | -2.56M | -3.04M | -3.11M | -5.42M | -3.53M | -2.90M | -2.66M | -962.40K | -1.36M | -1.04M | -2.70M | -998.11K | -2.20M |
| Net Income | -1.32M | -1.35M | -1.12M | -2.32M | -3.60M | -2.57M | -3.04M | -3.11M | -5.43M | -3.53M | -2.91M | -2.66M | -974.41K | -1.36M | -1.04M | -2.70M | -1.00M | -2.20M |
| Diluted EPS | - | - | - | - | - | - | -0.03 | -0.48 | -0.83 | -5.38 | -4.43 | -3.77 | -11.42 | -3.61 | -1.75 | -1.28 | -0.30 | -0.58 |
| R&D Expense | 308.85K | 474.91K | 234.26K | 916.41K | 1.75M | 873.65K | 1.38M | 1.53M | 2.89M | 2.37M | 2.00M | 1.91M | 206.57K | 311.09K | 447.11K | 1.74M | 176.28K | 1.28M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -4.42M | -4.95M | -12.32M | -14.87M | -9.94M | -4.50M | -8.77M |
| Net Income | -4.41M | -5.05M | -12.36M | -14.88M | -9.95M | -4.51M | -8.77M |
| Diluted EPS | - | - | -0.14 | -22.89 | -132.33 | -11.32 | -2.63 |
| R&D Expense | 1.07M | 1.31M | 5.20M | 7.45M | 6.46M | 1.41M | 3.63M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.81M | 2.91M | 14.52M | 5.92M | 631.59K | 4.60M | - | 2.08M |
| Total Equity | 316.92K | 821.71K | 2.01M | 13.35M | 3.05M | -2.59M | 3.97M | 2.20M | 733.21K |
| Cash & Equivalents | 42.61K | 90.28K | 1.93M | 14.06M | 5.14M | 376.05K | 3.95M | - | 710.69K |
| Total Liabilities | - | - | 899.64K | 1.16M | 2.87M | 3.23M | 634.76K | - | 1.35M |
| Current Liabilities | - | 992.31K | 899.64K | 1.16M | 2.87M | - | - | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.35M | -2.71M | -6.61M | -8.92M | -8.27M | -6.57M | -8.07M |
| Investing Cash Flow | 105.00K | 100.92K | -106.46K | - | -147.24K | -300.00K | - |
| Financing Cash Flow | 2.29M | 4.45M | 18.85M | 200 | 3.65M | 10.44M | 4.83M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | -536.7% | -250.7% | -92.6% | -488.5% | 383.5% | -113.8% | -1,196.4% |
| ROCE % | -538.4% | -246.0% | -92.3% | -488.3% | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kmt Wealth Management, LLC | 27.54% | 1.33M | $2.51M |
| 2 | Kingsbury Capital Investment Advisors LLC | 27.54% | 1.33M | $2.51M |
| 3 | Geode Capital Management, LLC | 0.55% | 26.37K | $49.84K |
| 4 | Vanguard Fiduciary Trust Co | 0.44% | 21.02K | $39.73K |
| 5 | Vanguard Capital Management LLC | 0.16% | 7.56K | $14.28K |
| 6 | Tower Research Capital LLC (TRC) | 0.07% | 3.52K | $6.65K |
| 7 | UBS Group AG | 0.05% | 2.35K | $4.45K |
| 8 | Blackrock Inc. | 0.01% | 437 | $825 |
| 9 | SBI Securities Co., Ltd. | - | 22 | $41 |
| 10 | IFG Advisory, LLC | - | 22 | $41 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALZN
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive dis…
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder (…
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive dis…
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive dis…
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive dis…
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder (…
ALZN — Frequently Asked Questions
What is the current share price of Alzamend Neuro, Inc. (ALZN)?
As of 2026-09-19 21:16 PDT, Alzamend Neuro, Inc. (ALZN) trades at $1.68 on NasdaqCM. Its 52-week range is $0.86 to $2.62.
What is the market capitalisation of ALZN?
Alzamend Neuro, Inc. (ALZN) has a market capitalisation of $8.11M on NasdaqCM.
What is the P/E ratio of ALZN?
ALZN trades at a trailing price-to-earnings (P/E) ratio of -0.64. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 9.77.
Is ALZN a good stock to buy?
This page provides a data-driven analysis of Alzamend Neuro, Inc. (ALZN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.